ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos ETM-28-2-12601 10.3892/etm.2024.12601 Articles Increased serum IL‑41 associated with acute exacerbation of chronic obstructive pulmonary disease CenTiantian 1 * HuangMinxuan 1 * LiMingcai 1 JinJie 1 DingQunli 1 LvDan 1 FeiLin 2 WangShanshan 1 MaHongying 1 Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, P.R. China Department of Respiratory and Critical Care Medicine, Cixi, Zhejiang 315300, P.R. China Correspondence to: Dr Hongying Ma, Department of Respiratory and Critical Care Medicine, Key Laboratory of Respiratory Disease of Ningbo, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Haishu, Ningbo, Zhejiang 315010, P.R. China fymahongying@nbu.edu.cn shijianguo1981@126.com

*Contributed equally

 08 2024 05 06 2024 28 2 312 14 11 2023 28 02 2024 Copyright: © 2024 Cen et al. 2024 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Interleukin (IL)-41 is a novel immunomodulatory cytokine involved in the pathogenesis of several inflammatory and metabolic illnesses. However, it remains unclear how IL-41 contributes to the pathogenesis of chronic obstructive pulmonary disease (COPD). Therefore, the aim of the present study was to explore the correlation between the expression level of IL-41 and acute exacerbation of COPD (AECOPD). In total, 107 patients with COPD and 56 healthy controls were recruited from the First Affiliated Hospital of Ningbo University (Ningbo, China). Serum IL-41, IL-6, and matrix metalloproteinase-2 (MMP-2) levels were evaluated using enzyme-linked immunosorbent assay. Serum amyloid A (SAA) and C-reactive protein (CRP) levels were assessed in the hospital laboratory. The levels of IL-41 were higher in the AECOPD group than in the stable COPD (SCOPD) and control groups (P<0.0001). IL-6, SAA and CRP levels, the percentage of neutrophils, as well as neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios were higher in the AECOPD group than those in the SCOPD and control groups. The smoking index was positively correlated with serum IL-41, CRP and SAA levels. The expression level of IL-41 was correlated with the number of acute exacerbations, severity of the exacerbations, and COPD assessment test scores in the AECOPD group. Examination of the receiver operating characteristic (ROC) curves showed that IL-41, especially when combined with other inflammatory factors, had a specific diagnostic value for AECOPD. According to the ROC curve analysis, the area under the curve (AUC) for IL-41 was 0.742 (P=0.051), and the AUC for IL-41 combined with other inflammatory factors was 0.925 (P=0.030). Increased serum IL-41 levels were associated with AECOPD and may play a role in the monitoring and evaluation of COPD.

 acute exacerbation chronic obstructive pulmonary disease interleukin-41 C-reactive protein serum amyloid A interleukin-6 Funding: This work was supported by the Natural Science Foundation of Ningbo (grant nos. 2021J242 and 2021J080) and the Key Research and Development Plan of Ningbo city (grant no. 2023Z179). Introduction

Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition characterized by chronic respiratory symptoms (dyspnea, cough and sputum production) caused by abnormalities in the airways (bronchitis and bronchiolitis) and/or alveoli (emphysema), which cause persistent, often progressive, airflow obstruction (1). Researchers have proposed adding the concept of ‘structural changes due to failed regeneration by the distal airways progenitor cells’ to the updated definition of COPD, highlighting the core traits of the disease and the demand for novel therapies (2). COPD is the most common chronic disease of the respiratory system and has a heavy economic burden. Factors contributing to the pathophysiology of COPD and leading to the degradation and regeneration of lung tissue include an imbalance in the protease and antiprotease systems, an imbalance in oxidation-antioxidant activity, and continuous airway inflammation (3).

Acute exacerbation of COPD (AECOPD) is mainly caused by infection or the inhalation of toxic gases. During acute exacerbation, the baseline symptoms of a patient, such as cough, expectoration, wheezing and dyspnea, deteriorate significantly. AECOPD is the leading cause of patient consultation and hospitalization. This hospitalization can lead to further decline in lung function, seriously affecting the quality of life of the patient, and shortening their life expectancy. Frequent hospitalization for COPD exacerbations has also been associated with higher mortality risk (4). Mortality in patients with severe AECOPD exceeds 20% within 1 year and 50% within 5 years (5). Compared with stable COPD (SCOPD), airway and systemic inflammation in AECOPD is further increased, and inflammatory mediators, cytokines and chemokines are released, causing inflammatory cells to enter the lung parenchyma and resulting in systemic inflammatory responses. Scholars worldwide are committed to identifying additional specific biomarkers in the blood to evaluate the disease, and have found that certain biomarkers have specific reference values for evaluating COPD.

Interleukin (IL)-41, a novel cytokine with immunoregulatory properties (6) often linked to anti-inflammatory effects, is also known as meteorin-like, glial cell differentiation regulator (Metrnl), cometin, subfatin, meteorin and IL-39(7). IL-41 mediates both pro-inflammatory and anti-inflammatory functions (8). The immune response is diminished when the production of IL-41 by M2 macrophages is blocked. IL-41 mutant mice experienced a more severe inflammatory injury in the liver, kidney, and particularly the uterus when injected with adenoviral vectors expressing LacZ or Metrnl (9). This implies that IL-41 is crucial for maintaining anti-inflammatory balance. In a clinical trial, increased inflammation and macrophage activity were primarily responsible for high IL-41 levels observed in smokers with AECOPD (10). However, compared with the general population, individuals who were discharged after an acute exacerbation had lower plasma IL-41 levels (11).

IL-6 is a cytokine with multiple functions that regulates the immune response, inflammation and tumor growth (5). Golestani et al (11) found that the concentration of IL-6 in exhaled breath condensate was markedly higher in patients with AECOPD than in those with SCOPD. The endopeptidase enzyme, matrix metalloproteinase-2 (MMP-2), separates extracellular matrix proteins (12). In patients with severe COPD, MMP-2 may facilitate processes that cause lung tissue deterioration (13). Serum amyloid A (SAA) is a precursor protein involved in AA amyloidosis and a polymorphic acute-phase protein secreted by hepatocytes that regulates innate immunity and cholesterol homeostasis (14). Prins et al (15) found that patients with AECOPD had considerably high levels of SAA. C-reactive protein (CRP) is a classic inflammatory marker for determining infection and inflammatory responses and reflects the total burden of systemic inflammation in an individual (16). Xu and Han (17) reported that CRP levels were related to the severity of AECOPD complicated by pneumonia. Another study revealed that the neutrophil percentage (NEU%), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) in the AECOPD group were considerably higher than those in the SCOPD and healthy control groups, suggesting NEU%, NLR and PLR may have specific values for the clinical diagnosis and treatment of AECOPD (18). The aim of the present study was to explore the correlation between IL-41 and AECOPD.

 Patients and methods <sec> <title>Study design

Patients with COPD and healthy controls were enrolled at the First Affiliated Hospital of Ningbo University (Ningbo, China) between March 2021 and November 2022. Among them, 51 patients (AECOPD group) and 56 (SCOPD group) were enrolled. A total of 56 healthy individuals who visited the hospital for an in-person checkup during the same period were selected as the healthy control group at the same time. The average age of the AECOPD group was (72.16±10.13) years, the average age of the SCOPD group was (69.32±10.06) years and the average age of the healthy control group was (70.07±6.12) years. The male/female ratio was 50/1 in the AECOPD group, 49/7 in the SCOPD group and 50/6 in the healthy control group. There were no significant differences in terms of gender and age among the three groups (P<0.05).

All individuals with COPD met the Global Initiative for Chronic Obstructive Lung Disease (GOLD) diagnostic criteria (19): i) The patient exhibited symptoms such as long-term recurrent cough, expectoration and dyspnea; ii) previous exposure to cigarette smoke and dust; and iii) pulmonary function test results showing a forced expiratory volume (FEV1)/forced vital capacity (FVC) ratio <70% after bronchodilator inhalation. Patients with other diseases that could cause similar symptoms and persistent airflow limitation were excluded.

An event that meets the diagnostic criteria for AECOPD was defined as one that worsens in <14 days; is characterized by increased dyspnea, cough and sputum; and may be accompanied by tachypnea and/or tachycardia. Such an event is frequently associated with increased local and systemic inflammation caused by infection, pollution, or other insults to the airways (20). The diagnostic criteria for SCOPD were as follows: Stable symptoms such as cough, expectoration and shortness of breath, or stable symptoms 1 month after an AECOPD event.

The exclusion criteria were as follows: i) Patients with bronchial asthma, bronchiectasis, interstitial lung disease, lung cancer or tuberculosis; ii) patients with severe immune system, brain, kidney, heart or blood diseases; and iii) other diseases that could cause elevated SAA, CRP, IL-6 and MMP-2 levels. As IL-41 is related to diabetes and coronary heart disease, patients with these conditions were excluded. The screening procedure is depicted in Fig. 1.

The Ethics Committee of the First Affiliated Hospital of Ningbo University (Ningbo, China) granted consent for the present study (approval no. 088RS-YJ01), and written informed consent was obtained from all participants. The study was conducted in accordance with the tenets put forth in the Declaration of Helsinki of 1964 and any subsequent modifications.

For pulmonary function testing: i) The participants sat during the examination, and pulmonary function tests were performed using a pulmonary function instrument (Portable pulmonary function testing instrument, X1; Xiamen XEEK Medical Equipment Co., Ltd.); ii) FVC, FEV1, FEV1/FVC (%) and FEV1% were recorded before and after administration of the tracheal dilator (albuterol, 400 µg) three times with an interval of 3 min, and the three results were averaged; iii) To reduce the influence of human factors, examinations were performed by the same professional, and the same pulmonary function instrument was used (calibration was required before each examination). Lung function in patients with acute exacerbations was measured 1 month after their condition had stabilized.

AECOPD blood samples were obtained at the time of admission, before antibiotics, hormones and other drugs were used. The drugs used in the SCOPD group were mainly inhaled drugs and oral expectorant drugs, and there was no study identified showing that these inhaled drugs and oral expectorant drugs cause the increase of CRP, SAA, IL-41 and MMP-2. IL-6 and MMP-2 levels were measured using enzyme-linked immunosorbent assay (ELISA) kits (cat. nos. KP00139 and KP00077, respectively; Wuhan Sanying Biotechnology) according to the manufacturer's instructions. IL-41 levels in serum were also measured using ELISA kits (cat. no. LV11160; Animalunion Biotechnology Co., Ltd) following the manufacturer's instructions. Serum CRP levels were assessed in a hospital laboratory using automated latex-enhanced immunoturbidimetric assays (cat. no. 105-004860-00; Shenzhen Mindray Biomedical Electronics Co., Ltd.), and mouse monoclonal anti-CRP antibody at a concentration of 1.4 mg/ml bound latex was included in the kit. Serum SAA levels were assessed in a hospital laboratory using the automated latex immunoturbidimetric assay [at. no. 8240-717(S); Ningbo Ruiyuan Biotechnology Co., Ltd.], and the kit contained appropriate concentrations of latex particles coated with mouse anti-human serum amyloid A antibody.

 Statistical analysis

GraphPad Prism (version 9; Dotmatics), SPSS (version 25; IBM Corp.), and MedCalc (version 22.009; MedCalc Software) were used for the data analysis, statistical analysis and plotting, respectively. Data are presented as the mean ± standard deviation (SD). Differences in continuous data between groups were compared using Student's t-test or the Mann-Whitney U-test, and the χ2-test was used for comparisons of categorical data. One-way analysis of variance was used to compare differences between multiple groups, and an independent samples t-test was used to compare differences between two groups. The post-hoc test used with ANOVA was Turkey's test. Pearson's correlation coefficient was used to analyze data conforming to a normal distribution. Spearman's rank correlation coefficient was used to analyze data that did not conform to a normal distribution. ROC curve analysis was used to examine the diagnostic value. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Study population

The present study included 107 patients with a confirmed COPD diagnosis. There were 51 patients diagnosed with AECOPD and 56 diagnosed with SCOPD. A total of 56 healthy controls who visited the hospital for in-person checkups during the recruitment period were also included in the analysis. There were no significant differences in sex, age or body mass index among the three groups (P>0.05). The baseline data of the patients are presented in Table I.

 Concentrations of IL-41 and other inflammatory factors in serum

IL-41, IL-6, SAA, and CRP levels were higher in the AECOPD group than those in the SCOPD and control groups (P<0.0001). The NEU%, NLR and PLR were also higher in the AECOPD group than in the SCOPD and control groups (P<0.05; Table I). Although the levels of IL-41, IL-6, SAA and CRP were higher in the SCOPD group than those in the control group, the differences were not statistically significant (Figs. 2 and 3). The levels of MMP-2 were lower in the control group than those in the SCOPD (P<0.001) and AECOPD groups (P<0.05) (Fig. 3). There was no significant difference in the level of MMP-2 between the AECOPD and SCOPD groups (Fig. 3).

 Correlation of the expression level of IL-41 with the number of acute exacerbations, severity of the exacerbation, PLR, smoking index, modified (British) Medical Research Council (mMRC) scores and COPD assessment test (CAT) scores

Only patients in the AECOPD group were included in the correlation analysis. ‘Number of acute exacerbations’ refers to the number of exacerbations in the past year. The degree of exacerbation in hospitalized patients was determined according to the clinical indicators of the patient as described in the 2023 GOLD report, which suggests three groups: No respiratory failure; acute respiratory failure, non-life-threatening; and acute respiratory failure, life-threatening (21).

With increased COPD severity, an overall increasing trend in the serum level of IL-41 was observed (Fig. 4). The correlations between the expression level of IL-41 and other factors were also analyzed. It was determined that the serum level of IL-41 was positively correlated with PLR (r=0.5602, P<0.001) and CAT score (r=0.3337, P<0.0015) in the AECOPD group (Fig. 5). It was also found that smoking index was positively correlated with serum IL-41 (r=0.3178, P=0.0245), CRP (r=0.2568, P=0.0011), and SAA (r=0.4249, P<0.0001) levels. However, smoking index was not correlated with serum IL-6 (r=0.05883, P=0.4557) or MMP-2 (r=0.1289, P=0.1011) levels (Fig. 6).

In conclusion, the levels of IL-41 were associated with the severity of AECOPD, as indicated by the correlation between IL-41 and the number of acute exacerbations, severity of exacerbation, and CAT scores in the AECOPD group.

 Diagnostic values of IL-41

In the included population, with a cutoff of 40.10 ng/l, the AUC, sensitivity and specificity of IL-41 to discriminate between AECOPD and SCOPD cases were 0.741 (95% confidence interval, 0.642-0.841; P<0.001), 58.82, and 96.43%, respectively (Fig. 7 and Table II).

There were significant differences in the AUC between IL-41 and IL-41 combined with IL-6 [0.839 (0.757-0.922), z=1.863, P=0.0625], IL-41 combined with SAA [0.891 (0.818-0.964), z=2.994, P=0.0028], IL-41 combined with CRP [0.881 (0.805-0.957), z=2.891, P=0.0038], and IL-41 combined with these three inflammatory factors [0.925 (0.865-0.984), z=3.493, P=0.0005]. There was a significant difference in the AUC between IL-41 combined with IL-6, and IL-41 combined with the three inflammatory factors [0.925 (0.865-0.984), z=2.812, P=0.0049] (Tables II and III).

 Discussion

The World Health Organization has estimated that 65 million individuals worldwide have mild-to-severe COPD, and its prevalence is increasing (22). In severe cases, admission to an intensive care center with passive or mechanical ventilation is necessary, resulting in considerable medical and economic burdens. Moreover, the diagnosis of COPD is subjective. Therefore, it is important to identify the biomarkers associated with AECOPD. There are two types of biomarkers for AECOPD: Pulmonary and systemic. Pulmonary biomarkers include IL-6, IL-8 and myeloperoxidase (23). Systemic biomarkers include CRP, procalcitonin, NLR and platelet distribution width values (24). However, no single biomarker has been widely used.

A previous study by Xu et al (25) also found that the FEV1, FEV1/FVC, and serum CRP, IL-6 and tumor necrosis factor (TNF)-α levels of patients with COPD in the smoking group were significantly lower than those of patients with COPD in the non-smoking group. The levels of CD+4 and CD+4/CD+8 were also significantly lower in smokers than those in non-smokers. It has been suggested that smoking may lead to impaired lung function in patients with COPD, which may subsequently aggravate airway inflammation and weaken T-lymphocyte immune function. Xian and Chen (26) found that FEV1 and diffusing capacity for carbon monoxide (DLCO%) of patients with AECOPD in the smoking group were significantly lower than those of patients with AECOPD in the non-smoking group and healthy controls. Furthermore, it was also revealed that the expression levels of serum cytokines such as procalcitonin, CRP, IL-6 and TNF-α were significantly higher in the smoking group than in the non-smoking and control groups. These findings indicate that the smoking status of patients with AECOPD is an important indicator of the expression of inflammatory factors. The findings in the present study revealed that the smoking index was positively correlated with serum IL-41, CRP and SAA levels.

IL-41 production is blocked in M2 macrophages, which reduces the immunological response. Numerous studies on the mechanism of action of macrophages in COPD have been published, drawing attention to the significance of macrophage polarization in the disease. ‘Macrophage polarization’ describes the geographical and temporal patterns of macrophage activation (27). In response to the synthesis of several signaling molecules and inflammatory factors, both conventionally activated (M1) and alternatively activated (M2) macrophage polarization is possible, demonstrating their high plasticity. In the lungs, M2 macrophages suppress inflammatory responses, whereas M1 macrophages promote them (28). By controlling macrophage polarization, IL-41 may contribute to the pulmonary inflammation associated with COPD; however, its specific role and mechanism require further study.

The findings of the present study indicate that, although IL-41 levels did not differ between the SCOPD and control groups, the IL-41 level was higher in the AECOPD group than those in the SCOPD and control groups. IL-6, SAA, CRP, NEU%, NLR and PLR values were higher in the AECOPD group than those in the SCOPD and control groups. IL-41 levels were also correlated with AECOPD severity. Compared with common inflammatory factors such as IL-6, CRP and SAA, IL-41 did not exhibit obvious superiority in diagnostic efficacy, but it did have high specificity. Use of a combination of factors significantly improved the efficiency of AECOPD diagnosis. A previous study by the authors also revealed that IL-41, which suppresses cigarette smoke-induced pulmonary inflammation in vivo in mice, can be used therapeutically to treat inflammatory lung conditions (29). According to earlier investigations, IL-41 level has been linked to diabetes and coronary heart disease, and the plasma IL-41 level in patients with AECOPD with diabetes mellitus and coronary heart disease was found to be lower than that in patients with AECOPD without diabetes and coronary heart disease (9). This implies that, during the acute phase, patients with AECOPD with diabetes and coronary heart disease do not generate a strong anti-inflammatory response. Therefore, we hypothesized that IL-41 level is elevated in patients with AECOPD and associated with AECOPD. IL-41 may inhibit inflammation by promoting macrophage polarization in the M2 direction and upregulate gene expression of M2 macrophages and their markers via a signal transduction pathway.

The present study did have some limitations. First, patients with diabetes or coronary heart disease were excluded. Second, the number of participants in this study was relatively limited, and the included population was predominantly male, indicating the study may have been affected by selection bias. The role of IL-41 in the pathophysiology of COPD requires further studies with larger sample sizes. The correlation between IL-41 level and sex also requires further exploration. Third, due to ethical reasons, it was very difficult to obtain tracheoscopic or ventilator secretions from COPD patients and analyze the correlation with the serum level of IL-41. The relationship between tracheoscopic or ventilator secretions from patients with COPD and the serum level of IL-41 may be addressed in a future study.

In conclusion, the expression level of IL-41 was increased in the serum of patients with AECOPD, indicating it may play a significant role in the inflammatory process of COPD and, especially, AECOPD. In the future, IL-41 may be a useful biomarker for the monitoring, evaluation and treatment of patients with AECOPD.

 Acknowledgements

Not applicable.

 Availability of data and materials

The data generated in the present study may be requested from the corresponding author.

 Authors' contributions

TC, MH and HM designed the study, wrote the manuscript. MH, ML and JJ collected clinical information and serum of the patients. ML, JJ, QD and DL designed and performed the statistical analysis. LF and SW performed the experiments. HM revised the manuscript (for intellectual content) and gave final approval for publication. TC, HM, JJ, ML, QD, DL, LF, SW and HM confirmed the authenticity of all the raw data. All authors have read and approved the final manuscript.

 Ethics approval and consent to participate

The Ethics Committee of the First Affiliated Hospital of Ningbo University (Ningbo, China) granted consent for the present study (approval no. 088RS-YJ01), and written informed consent was obtained from all participants. It is attested that the study was carried out considering the Declaration of Helsinki of 1964 and any subsequent changes.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References CelliBFabbriLCrinerGMartinezFJManninoDVogelmeierCMontes de OcaMPapiASinDDHanMKAgustiADefinition and nomenclature of chronic obstructive pulmonary disease: Time for its revisionAm J Respir Crit Care Med2061317132520223591408710.1164/rccm.202204-0671PP ConfalonieriMBragaLSaltonFRuaroBConfalonieriPChronic obstructive pulmonary disease definition: Is it time to incorporate the concept of failure of lung regeneration?Am J Respir Crit Care Med20736636720233617421010.1164/rccm.202208-1508LE ChristensonSASmithBMBafadhelMPutchaNChronic obstructive pulmonary diseaseLancet3992227224220223553370710.1016/S0140-6736(22)00470-6 PereraWRHurstJRWilkinsonTMSapsfordRJMüllerovaHDonaldsonGCWedzichaJAInflammatory changes, recovery and recurrence at COPD exacerbationEur Respir J2952753420071710799010.1183/09031936.00092506 WeiYWangSWangDLiuCExpression and clinical significance of serum amyloid A and interleukin-6 in patients with acute exacerbation of chronic obstructive pulmonary diseaseExp Ther Med192089209420203210427010.3892/etm.2019.8366 BridgewoodCRussellTWeedonHBaboolalTWatadASharifKCuthbertRWittmannMWechalekarMMcGonagleDThe novel cytokine Metrnl/IL-41 is elevated in Psoriatic Arthritis synovium and inducible from both entheseal and synovial fibroblastsClin Immunol20810825320193147008610.1016/j.clim.2019.108253 ZhengSLLiZYSongJLiuJMMiaoCYMetrnl: A secreted protein with new emerging functionsActa Pharmacol Sin3757157920162706321710.1038/aps.2016.9 UshachIArrevillaga-BoniGHellerGNPoneEHernandez-RuizMCatalan-DibeneJHeveziPZlotnikAMeteorin-like/Meteorin-β is a novel immunoregulatory cytokine associated with inflammationJ Immunol2013669367620183046405110.4049/jimmunol.1800435 RaoRRLongJZWhiteJPSvenssonKJLouJLokurkarIJedrychowskiMPRuasJLWrannCDLoJCMeteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesisCell1571279129120142490614710.1016/j.cell.2014.03.065 KergetBAfşinDEKergetFAşkınSAkgünMIs metrnl an adipokine involved in the anti-inflammatory response to acute exacerbations of COPD?Lung19830731420203196016410.1007/s00408-020-00327-4 GolestaniRRazavianMYeYZhangJJungJJToczekJGonaKKimHYEliasJALeeCGMatrix metalloproteinase-targeted imaging of lung inflammation and remodelingJ Nucl Med5813814320172746936110.2967/jnumed.116.176198 AlrumaihiFA cheminformatics-biophysics correlate to identify promising lead molecules against matrix metalloproteinase-2 (MMP-2) enzyme: A promising anti-cancer targetSaudi Pharm J311244125320233728441510.1016/j.jsps.2023.05.010 ZhangYLiYYeZMaHExpression of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and changes in alveolar septa in patients with chronic obstructive pulmonary diseaseMed Sci Monit26e92527820203307014710.12659/MSM.925278 TanakaMTakaradaTNadanakaSKojimaRHosoiKMachibaYKitagawaHYamadaTInfluences of amino-terminal modifications on amyloid fibril formation of human serum amyloid AArch Biochem Biophys74210961520233710551210.1016/j.abb.2023.109615 PrinsHJDuijkersRKramerGBoerhoutERietemaFJde JongPASchoorlMIvan der WerfTSBoersmaWGRelationship between biomarkers and findings on low-dose computed tomography in hospitalised patients with acute exacerbation of COPDERJ Open Res800054202220223574723310.1183/23120541.00054-2022 TanQWangBYeZMuGLiuWNieXYuLZhouMChenWCross-sectional and longitudinal relationships between ozone exposure and glucose homeostasis: Exploring the role of systemic inflammation and oxidative stress in a general Chinese urban populationEnviron Pollut32912171120233710037210.1016/j.envpol.2023.121711 XuBHanLPredictive Value of CRP, PCT and ESR on piperacillin-tazobactam in treating chronic obstructive pulmonary disease with pneumoniaClin Lab6920233705795210.7754/Clin.Lab.2022.220640 HanFangBinZhaoDonghong Liu(2020) To explore the clinical value of NLR and PLR in the treatment of acute exacerbation of chronic obstructive pulmonary diseaseGeneral practice clinical and education186946972020 VenkatesanPGOLD COPD report: 2024 updateLancet Respir Med12151620243806138010.1016/S2213-2600(23)00461-7 CelliBRFabbriLMAaronSDAgustiABrookRCrinerGJFranssenFMEHumbertMHurstJRO'DonnellDAn updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The rome proposalAm J Respir Crit Care Med2041251125820213457099110.1164/rccm.202108-1819PP AgustíACelliBRCrinerGJHalpinDAnzuetoABarnesPBourbeauJHanMKMartinezFJMontes de OcaMGlobal initiative for chronic obstructive lung disease 2023 report: GOLD executive summaryEur Respir J61230023920233685844310.1183/13993003.00239-2023 GautamSSO'TooleRFConvergence in the epidemiology and pathogenesis of COPD and pneumoniaCOPD1379079820162731041610.1080/15412555.2016.1191456 KoutsokeraAKostikasKNicodLPFittingJWPulmonary biomarkers in COPD exacerbations: A systematic reviewRespir Res1411120132414394510.1186/1465-9921-14-111 RamyaPAMohapatraMMSakaVKKarRChakkalakkoombilSVVemuriMBHaematological and inflammatory biomarkers among stable COPD and acute exacerbations of COPD patientsSultan Qaboos Univ Med J2323924420233737782910.18295/squmj.12.2022.062 XuHaifengSunYifengLinHuanEffects of smoking on immune inflammatory response and pulmonary function in patients with chronic obstructive pulmonary diseaseJ Clin Pulmonol2558612020 XianShaojingChenQingyunChanges of lung function and serum cytokine levels in patients with acute exacerbation of chronic obstructive pulmonary disease and their correlation with smoking and body mass indexJ Clin & Pathology421441502021 MurrayPJMacrophage PolarizationAnnu Rev Physiol7954156620172781383010.1146/annurev-physiol-022516-034339 BazzanETuratoGTinèMRaduCMBalestroERigobelloCBiondiniDSchiavonMLunardiFBaraldoSDual polarization of human alveolar macrophages progressively increases with smoking and COPD severityRespir Res184020172823182910.1186/s12931-017-0522-0 CenTMaiYJinJHuangMLiMWangSMaHInterleukin-41 diminishes cigarette smoke-induced lung inflammation in miceInt Immunopharmacol124(Pt A)11079420233761144410.1016/j.intimp.2023.110794

Inclusion and exclusion criteria for patients with COPD and HC. COPD, chronic obstructive pulmonary disease; HC, healthy controls; CRP, C-reactive protein; SAA, serum amyloid A; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SCOPD, stable chronic obstructive pulmonary disease.

Concentrations of IL-41 in serum. ****P<0.0001. IL-41, interleukin-41; SCOPD stable chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; ns, not significant.

Concentrations of serum cytokines. Concentrations of (A) IL-6, (B) MMP-2, (C) SAA and (D) CRP in serum. *P<0.05, ***P<0.001 and ****P<0.0001. IL-6, interleukin 6; MMP-2, matrix metalloproteinase-2; SAA, serum amyloid A; CRP, C-reactive protein; SCOPD, stable chronic obstructive pulmonary disease; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; ns, not significant.

Relationship between IL-41 and AECOPD. (A) Concentrations of IL-41 according to the number of acute exacerbations. (B) The concentrations of IL-41 according to degree of the exacerbation in hospitalized patients. (C) Concentrations of IL-41 according to mMRC. *P<0.05, **P<0.01 and ****P<0.0001. IL-41, interleukin-41; mMRC, modified (British) Medical Research Council; ns, not significant.

Correlation of IL-41 with CAT and PLR. (A) Correlation of IL-41 with CAT. r=0.3337, P=0.0015. (B) Correlation of IL-41 with PLR. r=0.5602, P<0.001. IL-41, interleukin-41; CAT, chronic obstructive pulmonary disease assessment test; PLR, platelet to lymphocyte ratio.

Correlation of smoking index and serum cytokines. (A) Correlation of IL-41 with smoking index. r=0.3178, P=0.0245. (B) Correlation of CRP with smoking index. r=0.2568, P=0.0011. (C) Correlation of SAA with smoking index. r=0.4249, P<0.0001. (D) Correlation of IL-6 with smoking index. r=0.05883, P=0.4557. (E) Correlation of MMP-2 with smoking index. r=0.1289, P=0.1011. IL-41, interleukin-41; CRP, C-reactive protein; SAA, serum amyloid A; IL-6, interleukin 6; MMP-2, matrix metalloproteinase-2.

ROC curves. (A) ROC curves indicating the diagnostic value of IL-41, IL-6, SAA and CRP in AECOPD and SCOPD. (B) ROC curves indicating the diagnostic value of IL-41 combined with IL-6, MMP-2, SAA and CRP in AECOPD and SCOPD. ROC, receiver operating characteristic; IL-41, interleukin-41; IL-6, interleukin 6; MMP-2, matrix metalloproteinase-2; SAA, serum amyloid A; CRP, C-reactive protein; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SCOPD, stable chronic obstructive pulmonary disease.

Comparison of age, sex, BMI, smoking Index, CRP, SAA, IL-6 and MMP-2 in the study groups.

Variable Control SCOPD AECOPD
Age, years 70.07±6.12 69.32±10.06 72.16±10.13
Sex, male/female 50/6 49/7 50/1
BMI, kg/m2 22.79±3.22 22.75±3.18 21.48±3.00
Smoking index, pack years 6.07±14.48 28.84±28.51a 35.62±28.95b
CRP, mg/l 1.79±1.52 1.85±1.71a 41.15±56.48b
SAA, mg/l 3.33±1.98 3.83±2.85a 113.0±107.3b
IL-6, ng/l 17.28±6.52 18.37±6.12a 36.37±34.33b
MMP-2, ng/l 255±107.1 334.1±106.7 309.9±113.7b
WBC, 109/l 5.92±1.53 6.36±1.76a 7.66±3.00b
NEU% 58.20±9.37c 64.49±9.13a 73.52±9.86b
NLR 1.98±1.01 2.93±1.60a 6.05±4.12b
PLR 128.6±51.93 144.6±60.55a 209.2±95.89b
FEV1/FVC, % 85.83±4.37 55.83±10.22a 51.22±11.86b
FEV1%pred 108.1±16.79 52.33±21.10a 40.87±15.85b

Data are presented as the mean ± SD or median (25-75th centile). Differences in continuous data between groups were compared using Student's t-test or the Mann-Whitney U-test, and the χ2-test was used for comparisons of categorical data.

aP<0.05, compared with AECOPD group;

bP<0.05, compared with the control group;

cP<0.05, compared with SCOPD group. BMI, body mass index; CRP, C-reactive protein; SAA, serum amyloid A; IL-6, interleukin-6; MMP-2, matrix metalloproteinase-2; WBC, white blood cell count; NEU%, neutrophil percentage; NLR, neutrophil-to-lymphocyte; PLR, platelet to lymphocyte ratio; FEV1/FVC (%), ratio of forced expiratory volume in the first second to forced vital capacity; FEV1%pred, forced expiratory volume in the first second as percentage of predicted volume; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SCOPD, stable chronic obstructive pulmonary disease.

Diagnostic performance of IL-41, IL-6, SAA and CRP in differentiating AECOPD from SCOPD.

Variables AUC Cutoff Sensitivity, % Specificity, % Accuracy, % Youden index Std. error
IL-41 0.741 40.10 58.82 96.43 78.50 0.310 0.051
IL-6 0.809 20.01 80.50 81.00 80.38 0.615 0.051
SAA 0.900 10.55 73.20 100.00 87.23 0.732 0.034
CRP 0.889 3.15 82.90 85.70 84.10 0.686 0.037
IL-41 + IL-6 0.839 N.A. 74.50 89.30 82.24 0.630 0.042
IL-41 + MMP-2 0.738 N.A. 62.70 91.10 77.57 0.538 0.051
IL-41 + CRP 0.885 N.A. 72.00 100.00 86.92 0.720 0.035
IL-41 + SAA 0.891 N.A. 75.60 100.00 88.79 0.756 0.037
IL-41 + IL-6 + MMP-2 + SAA + CRP 0.925 N.A. 82.90 95.20 88.79 0.781 0.030
IL-41 + IL-6 + SAA + CRP 0.925 N.A. 82.90 95.20 88.79 0.782 0.030

IL-41, interleukin-41; IL-6, interleukin 6; SAA, serum amyloid A; CRP, C-reactive protein; AECOPD, acute exacerbation of chronic obstructive pulmonary disease; SCOPD, stable chronic obstructive pulmonary disease; AUC, area under the curve; Std. standard; MMP-2, matrix metalloproteinase-2. N.A., not available.

Differences between the area under the curves.

Variables P-value Z-value
IL-41 and IL-41+ IL-6 0.0625 1.863
IL-41 and IL-41 + MMP-2 0.4694 0.723
IL-41 and IL-41 + SAA 0.0028 2.994
IL-41 and IL-41 + CRP 0.0038 2.891
IL-41 and IL-6 + SAA + CRP 0.0005 3.493
IL-41 + IL-6 and IL-41 + IL-6 + SAA + CRP 0.0049 2.812
IL-41 + SAA and IL-41 + IL-6 + SAA + CRP 0.1082 1.606
IL-41+ CRP and IL-41 + IL-6 + SAA + CRP 0.1456 1.455

IL-41, interleukin-41; IL-6, interleukin-6; MMP-2, matrix metalloproteinase-2; SAA, serum amyloid A; CRP, C-reactive protein.